Palladium Partners’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | $224K | Buy |
3,764
+64
| +2% | +$4.09K | 0.01% | 309 |
|
|
2021
Q4 | $269K | Hold |
3,700
| – | – | 0.01% | 300 |
|
|
2021
Q3 | $258K | Sell |
3,700
-48
| -1% | -$3.37K | 0.01% | 263 |
|
|
2021
Q2 | $258K | Buy |
3,748
+141
| +4% | +$9.41K | 0.01% | 256 |
|
|
2021
Q1 | $233K | Sell |
3,607
-139
| -4% | -$8.96K | 0.01% | 261 |
|
|
2020
Q4 | $218K | Buy |
3,746
+10
| +0.3% | +$603 | 0.01% | 242 |
|
|
2020
Q3 | $236K | Sell |
3,736
-210
| -5% | -$14.6K | 0.01% | 228 |
|
|
2020
Q2 | $304K | Buy |
3,946
+246
| +7% | +$18.9K | 0.02% | 206 |
|
|
2020
Q1 | $277K | Hold |
3,700
| – | – | 0.02% | 204 |
|
|
2019
Q4 | $240K | Sell |
3,700
-1,150
| -24% | -$74.9K | 0.02% | 244 |
|
|
2019
Q3 | $374K | Buy |
4,850
+1,150
| +31% | +$75.2K | 0.03% | 206 |
|
|
2019
Q2 | $250K | Sell |
3,700
-200
| -5% | -$13.2K | 0.02% | 242 |
|
|
2019
Q1 | $254K | Sell |
3,900
-50
| -1% | -$3.32K | 0.02% | 236 |
|
|
2018
Q4 | $247K | Sell |
3,950
-900
| -19% | -$62.9K | 0.02% | 227 |
|
|
2018
Q3 | $374K | Sell |
4,850
-560
| -10% | -$42.3K | 0.03% | 215 |
|
|
2018
Q2 | $383K | Sell |
5,410
-250
| -4% | -$17.7K | 0.03% | 212 |
|
|
2018
Q1 | $427K | Sell |
5,660
-365
| -6% | -$29K | 0.03% | 203 |
|
|
2017
Q4 | $432K | Sell |
6,025
-635
| -10% | -$48.2K | 0.03% | 201 |
|
|
2017
Q3 | $540K | Buy |
6,660
+155
| +2% | +$11.9K | 0.04% | 188 |
|
|
2017
Q2 | $460K | Sell |
6,505
-1,002
| -13% | -$66.7K | 0.04% | 193 |
|
|
2017
Q1 | $510K | Sell |
7,507
-6,052
| -45% | -$426K | 0.04% | 186 |
|
|
2016
Q4 | $971K | Sell |
13,559
-66,927
| -83% | -$4.97M | 0.08% | 149 |
|
|
2016
Q3 | $6.37M | Sell |
80,486
-18,454
| -19% | -$1.5M | 0.56% | 55 |
|
|
2016
Q2 | $8.25M | Buy |
98,940
+687
| +0.7% | +$61K | 0.75% | 39 |
|
|
2016
Q1 | $9.03M | Buy |
98,253
+5,725
| +6% | +$516K | 0.83% | 40 |
|
|
2015
Q4 | $9.36M | Buy |
92,528
+9,552
| +12% | +$994K | 0.87% | 38 |
|
|
2015
Q3 | $8.15M | Buy |
82,976
+28,137
| +51% | +$3.12M | 0.8% | 38 |
|
|
2015
Q2 | $6.42M | Buy |
54,839
+5,885
| +12% | +$643K | 0.57% | 56 |
|
|
2015
Q1 | $4.8M | Buy |
48,954
+41,319
| +541% | +$4.2M | 0.41% | 73 |
|
|
2014
Q4 | $720K | Buy |
7,635
+420
| +6% | +$43.4K | 0.06% | 178 |
|
|
2014
Q3 | $768K | Sell |
7,215
-120
| -2% | -$11.8K | 0.07% | 172 |
|
|
2014
Q2 | $608K | Sell |
7,335
-190
| -3% | -$14.8K | 0.05% | 183 |
|
|
2014
Q1 | $533K | Sell |
7,525
-1,475
| -16% | -$116K | 0.05% | 191 |
|
|
2013
Q4 | $676K | Sell |
9,000
-210
| -2% | -$14.6K | 0.06% | 182 |
|
|
2013
Q3 | $579K | Buy |
9,210
+75
| +0.8% | +$4.48K | 0.06% | 185 |
|
|
2013
Q2 | $468K | Buy |
+9,135
| New | +$476K | 0.05% | 191 |
|
Other funds holding GILD
Palladium Partners's GILD Position: Q1 2022 in Review
Palladium Partners increased its Gilead Sciences (GILD) stake by 1.7% in Q1 2022, buying an estimated $4.09K and bringing the position to 3,764 shares worth $224K. The position accounts for 0.01% of the portfolio, ranked #309.
Palladium Partners first reported a position in GILD in Q2 2013 and has held it in 36 quarters since. The position peaked at $9.36M in Q4 2015. 1,601 funds tracked by Wall St. Rank hold GILD as of Q1 2022.
- Palladium Partners held 3,764 shares of Gilead Sciences worth $224K as of Q1 2022.
- Palladium Partners bought 64 Gilead Sciences shares in Q1 2022, an estimated $4.09K.
- Gilead Sciences made up 0.01% of Palladium Partners's portfolio in Q1 2022, its #309 holding.
- Palladium Partners first reported a position in Gilead Sciences in Q2 2013 and has held it in 36 quarters since.
- Palladium Partners's Gilead Sciences position peaked at $9.36M in Q4 2015.
- 1,601 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2022.
Based on Palladium Partners's 13F filing for Q1 2022, filed 26 Apr 2022.